- Home
- ACA vs AKRO Comparison
ACA vs AKRO Comparison
Compare ACA & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACA
- AKRO
- Stock Information
- Founded
- ACA 2018
- AKRO 2017
- Country
- ACA United States
- AKRO United States
- Employees
- ACA N/A
- AKRO N/A
- Industry
- ACA Metal Fabrications
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- ACA Industrials
- AKRO Health Care
- Exchange
- ACA Nasdaq
- AKRO Nasdaq
- Market Cap
- ACA 4.8B
- AKRO 3.9B
- IPO Year
- ACA N/A
- AKRO 2019
- Fundamental
- Price
- ACA $89.82
- AKRO $54.52
- Analyst Decision
- ACA Buy
- AKRO Strong Buy
- Analyst Count
- ACA 3
- AKRO 8
- Target Price
- ACA $104.00
- AKRO $82.50
- AVG Volume (30 Days)
- ACA 191.4K
- AKRO 2.0M
- Earning Date
- ACA 07-31-2025
- AKRO 08-08-2025
- Dividend Yield
- ACA 0.22%
- AKRO N/A
- EPS Growth
- ACA N/A
- AKRO N/A
- EPS
- ACA 1.59
- AKRO N/A
- Revenue
- ACA $2,603,300,000.00
- AKRO N/A
- Revenue This Year
- ACA $13.58
- AKRO N/A
- Revenue Next Year
- ACA $6.06
- AKRO N/A
- P/E Ratio
- ACA $56.57
- AKRO N/A
- Revenue Growth
- ACA 10.44
- AKRO N/A
- 52 Week Low
- ACA $68.11
- AKRO $21.02
- 52 Week High
- ACA $113.43
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- ACA 62.60
- AKRO 70.35
- Support Level
- ACA $86.81
- AKRO $52.28
- Resistance Level
- ACA $90.61
- AKRO $57.07
- Average True Range (ATR)
- ACA 1.80
- AKRO 2.71
- MACD
- ACA 0.12
- AKRO 0.73
- Stochastic Oscillator
- ACA 89.52
- AKRO 78.98
About ACA Arcosa Inc.
Arcosa Inc is a manufacturer and producer of infrastructure-related products and services. It operates in three segments: Construction Products, Engineered Structures, and Transportation Products. The Construction Products segment produces and sells construction aggregates and manufactures and sells trench shields and shoring products and services for infrastructure-related projects. The Transportation Products segment manufactures and sells products for the inland waterway and rail transportation industries. The Engineered Structures segment manufactures and sells products for energy-related businesses, including structural wind towers, telecommunication structures, steel utility structures for electricity transmission and distribution, and storage and distribution containers.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.